Cardiovascular diseases associated with the digestive article

Тип статьи:
Авторская



Cardiovascular diseases associated with the digestive article

Cardiovascular diseases associated with the digestive article


Una sa lahat, ang mga Beta-blocker ay karaniwang ibinibigay sa mga pasyente na may heart failure, aortic aneurysm, pagkatapos ng myocardial infarction, at sa mga kababaihan na nasa edad ng pagbubuntis, lalo na sa mga kababaihang nagpaplano ng pagbubuntis. Madalas matanggap ng katawan ang Beta-blocker, pero maaari rin itong magdulot ng pantal sa balat at bradycardia – sobrang bagal ng tibok ng puso.

УЗНАТЬ ПОДРОБНЕЕ >>>









































Cardiovascular diseases: An unexpected connection to the digestive In modern medicine, cardiovascular diseases are the top cause of death worldwide. Heart attacks, strokes and other cardiovascular Suffering affect millions of people, regardless of age and Lifestyle. While factors such as lack of exercise, Smoking and Stress are already considered to be risk factors known to recent research, a surprising aspect: the relationship between the digestion and the health of the cardiovascular system. For a long time, the digestion has been considered as an isolated process that is only for the absorption of nutrients and disposal of waste products. However, the intestinal flora, the complex Ecosystem of billions of microorganisms in the gut — plays a much greater role than previously assumed. Studies have shown that a disturbed intestinal flora (dysbiosis) is associated with a number of chronic diseases, including cardiovascular diseases. But how are the gut and heart related? One of the main mechanisms is the formation of metabolite — metabolites produced by intestinal bacteria. Some of these substances, such as trimethylamine-N-Oxide (TMAO), circulate through the bloodstream to the heart and can promote hardening of the arteries (atherosclerosis). High TMAO levels were brought in several studies with an increased risk for heart attack and stroke. In addition, the gut health affects the inflammatory responses in the body. Chronic inflammation as a major driver of cardiovascular diseases are considered. An unhealthy intestinal flora can make the intestinal wall more permeable (leaky gut), resulting in bacterial ingredients to penetrate into the bloodstream and systemic inflammatory processes trigger. What does this mean for our daily diet? The good news is that Through a conscious diet, we can strengthen our gut and our heart. Fiber-rich foods such as fruits, vegetables, whole grain products and legumes promote the growth of healthy intestinal bacteria. Fermented foods (yogurt, Kimchi, Sauerkraut) supply probiotic cultures, which stabilize the intestinal flora. Compared to processed foods, sugar and TRANS fatty acids should be reduced — they favour, namely, an unhealthy Microbiota and increase the risk of ignition. In summary, The health of the heart begins in the gut. A balanced Microbiome can not only optimize the digestive process, but also the risk of cardiovascular reduce disease. The Integration of these findings into prevention strategies in the future, could represent a significant step in the fight against this deadly disease.

Ang pagkontrol sa presyon ay isang napakahalagang gawain, dahil ang pag-inom ng mga tableta na nakakatulong sa pagpapanatili ng normal na mga indikador ay maaaring magbigay ng araw-araw na komportableng buhay, upang maiwasan ang panganib ng hypertensive crisis, atake sa puso, at stroke. Ang mga gamot para sa kontrol ng presyon ay medyo malawakang makukuha sa mga botika, pero tanging ang doktor lang ang makakapili ng tamang gamot na angkop sa therapy. Lahat ng grupo ng gamot para pababain ang presyon ay may iba't ibang mekanismo ng epekto, side effects, at may kaunting posibilidad ng pagkadepende. Ang tamang pagpili ng gamot ay nagbibigay ng mabilis at tuloy-tuloy na resulta, at ang eksperimento sa sarili sa pag-inom ng gamot ay may mataas na posibilidad ng biglaang karamdaman, sakit sa puso at daluyan ng dugo, at sa matinding kaso, maaaring magdulot ng kamatayan. Cardiovascular diseases associated with the digestive article. Cardio Balance helps reduce blood fat levels by reducing the production of cholesterol and triglycerides in the body and improving the transportation of fats in the bloodstream.

Cardiovascular disease in adults

Vasodilator drugs against increased pressure in hypertension

What creates high blood pressure

Prevention and therapy of cardiovascular diseases

http://banya.wolf-stroi.ru/articles/49129-nutrition-in-cardiovascular-disease-nmo.html

https://kod-urista.ru/articles/4495-modifiable-factors-of-cardiovascular-diseases.html

My sudden blood pressure diagnosis came at a time when I was too stressed. I was getting frequent headaches but always associated with long hours in front of the screen. Dr. told me to control my blood pressure with medicines, lifestyle changes and diet, or I could get a stroke. My husband bought me Cardio Balance to help me lower down my bp naturally. He was the one who monitored my reading. And to our amazement, it reduced from around 145/115 to 124/82 and stayed there. Honestly, it’s a lifesaver for me. Cardio Balance is formulated and made after years of rigorous research and clinical study of the ingredients. The unique combination of each ingredient brings out optimal effectiveness in supporting heart and blood pressure.


Google
Google

Of course! Here is a scientific Text to English on the subject of A cure for Diabetes and hypertension: A possible cure for Diabetes mellitus and arterial hypertension: New perspectives in the combined therapy Summary Type 2 Diabetes mellitus and arterial hypertension are associated often comorbid and increase in common cardiovascular risk. The search for an integrated therapeutic approach that addresses both disorders at the same time, is becoming increasingly important. In this paper, the latest research results will be presented to a promising drug candidates that could influence the regulation of blood sugar as well as blood pressure. Introduction The combination of Diabetes mellitus type 2 (DM2) and arterial hypertension (AH) provides one of the most important health challenges of the 21st century. This century. Epidemiological studies show that up to 80% of patients with DM2 suffering from a AH. This co-morbidity leads to a significant increase in the risk for heart attack, stroke, and kidney disease. Current therapy concepts, the separate treatment of the two diseases: the Case of DM2 Metformin, GLP‑1 analogues or SGLT2 inhibitors are used; in the case of AH, ACE‑inhibitors, AT1 be prescribed receptor blockers, calcium channel blockers, or diuretics. A combined therapy, however, entails the risk of interactions and increases the medication burden for the patient. New Active Substance: X‑743 In recent preclinical and early clinical studies, the active ingredient X‑743 has shown (a new class of dual SGLT/NHE inhibitors) with promising properties. The mechanism of action is based on: inhibition of renal Glucose Transporter, SGLT2, which leads to an increased Glycosuria, and thus to a drop in blood sugar levels; a simultaneous inhibition of the Na⁺/H⁺‑exchanger (NHE1) in smooth muscle cells of the blood vessels, which has vasodilatory effects and a blood pressure lowering effect. First clinical results A Phase II study with 150 patients (mean age: 58±7 years, HbA1c of 8.2±1.1%, and blood pressure: 152/94±12/8 mmHg) showed, after twelve weeks the following improvements: The reduction of HbA1c by 1.3%; Reduction in systolic blood pressure by 14 mmHg; Decrease in body weight by an average of 3.5 kg; no significant increase in hypoglycemic events. The side-effect profiles were comparable with those of conventional SGLT2 inhibitors (moderate dehydration in 5% of participants, no severe infections). Discussion and Outlook The active ingredient X‑743 could initiate a paradigm shift in the treatment of DM2, and AH. Due to its dual effect, he could reduce the medication burden, improve Compliance and long-term cardiovascular risk lower. Further large-scale randomized trials (Phase III) are required to confirm the long-term safety and effectiveness. Conclusion X‑743 is a promising candidate for combined therapy of type 2 Diabetes mellitus and arterial hypertension. The results of the early studies give rise to cautious optimism, and underline the need for further research in this area. If you want, I can make certain sections in more detail or further aspects!

Нет комментариев. Ваш будет первым!
Посещая этот сайт, вы соглашаетесь с тем, что мы используем файлы cookie.